The|DET shares|NOUN of|ADP Dr_Reddy’s_Laboratories|ENT rebounded|VERB over|ADP the_last_two_sessions|DATE after|ADP it|PRON touched|VERB its|ADJ 52-week_low|NOUN last_Friday|DATE ,|PUNCT post|NOUN -|PUNCT announcement|NOUN of|ADP its|ADJ fourth-quarter_results|NOUN .|PUNCT
There|ADV is|VERB renewed|VERB interest|NOUN in|ADP the|DET stock|NOUN from|ADP the|DET investor_fraternity|NOUN ,|PUNCT in|ADP the|DET belief|NOUN that|ADP the|DET ongoing_regulatory_issues|NOUN have|VERB been|VERB factored|VERB in|ADP to|ADP the|DET share_price|NOUN ,|PUNCT creating|VERB a|DET buying_opportunity|NOUN for|ADP the|DET medium_term|NOUN .|PUNCT
Last_Friday|DATE ,|PUNCT following|VERB the|DET declaration|NOUN of|ADP its|ADJ Q4_results|NOUN ,|PUNCT the|DET stock|NOUN corrected|VERB to|ADP its|ADJ lowest_level|NOUN in|ADP the_last_one_year|DATE ,|PUNCT shedding|VERB over_42|CARDINAL per_cent|NOUN from|ADP its|ADJ peak|NOUN seen|VERB in|ADP late_July_2016|DATE .|PUNCT
On|ADP Monday|DATE ,|PUNCT the|DET stock|NOUN gained|VERB more_than_3|CARDINAL per_cent|NOUN .|PUNCT
Consecutively|ADV ,|PUNCT the|DET share_price|NOUN rose|VERB about_2|CARDINAL per|NOUN cent|NOUN in|ADP early_trade|NOUN on|ADP Tuesday|DATE .|PUNCT
The|DET correction|NOUN in|ADP the|DET share_prices|NOUN can|VERB be|VERB attributed|VERB to|ADP regulatory_inspections|NOUN of|ADP its|ADJ three|CARDINAL facilities|NOUN by|ADP the|DET USFDA|ENT .|PUNCT
The|DET company|NOUN received|VERB USFDA_warning_letters|NOUN regarding|VERB deviations|NOUN from|ADP current_good_manufacturing_practices|NOUN (|PUNCT cGMP|PROPN )|PUNCT at|ADP its|ADJ active_pharmaceutical_ingredients|NOUN (|PUNCT APIs|NOUN )|PUNCT plants|NOUN at|ADP Srikakulam|ENT and|CCONJ Miryalaguda|ENT and|CCONJ for|ADP violations|NOUN at|ADP its|ADJ oncology_formulation_facility|NOUN at|ADP Duvvada|ENT .|PUNCT
These|DET led|VERB to|ADP a|DET disruption|NOUN in|ADP supplies|NOUN ,|PUNCT delays|NOUN in|ADP approvals|NOUN and|CCONJ remedial_costs|NOUN .|PUNCT
All|ADJ this|DET ,|PUNCT in|ADP turn|NOUN ,|PUNCT impacted|VERB the|DET revenue|NOUN of|ADP the|DET company|NOUN badly|ADV .|PUNCT
The_US|ENT FDA|ENT ,|PUNCT however|ADV ,|PUNCT completed|VERB its|ADJ re-inspection|NOUN of|ADP these|DET facilities|NOUN during|ADP March|DATE and|CCONJ April_2017|DATE and|CCONJ issued|VERB a|DET Form|PROPN 483|CARDINAL with|ADP 11|CARDINAL observations|NOUN .|PUNCT
The|DET issue|NOUN of|ADP Form_483|CARDINAL implies|VERB that|ADP the|DET USFDA|ENT has|VERB found|VERB minor_deviations|NOUN in|ADP manufacturing_practices|NOUN that|ADJ need|VERB to|PART be|VERB addressed|VERB .|PUNCT
The|DET remediation_measures|NOUN with|ADP respect|NOUN to|ADP these|DET key_facilities|NOUN is|VERB important|ADJ for|ADP the|DET company|NOUN as|ADP they|PRON continue|VERB to|PART weigh|VERB on|ADP the|DET overall_performance|NOUN .|PUNCT
Q4|PROPN results|VERB __Dr_Reddy’s_Lab|ENT reported|VERB a|DET 175_per|MONEY cent_growth|NOUN in|ADP consolidated_net_profit|NOUN to|PART Rs|VERB .|PUNCT
337.6|CARDINAL crore|NOUN in|ADP the_March_quarter|DATE as|ADP against|ADP Rs_122.6|CARDINAL crore|NOUN seen|VERB in|ADP the|DET same_period|NOUN last_year|DATE .|PUNCT
The|DET nearly_three-fold_jump|NOUN in|ADP the|DET bottom-line|NOUN was|VERB attributable|ADJ to|ADP the|DET low_base|NOUN in|ADP the_corresponding_quarter_of|DATE Q4FY16|ENT ,|PUNCT which|ADJ was|VERB impacted|VERB due|ADP to|ADP the|DET writing|NOUN down|ADP of|ADP receivables|NOUN worth|ADJ Rs|NOUN 400|CARDINAL crore|NOUN from|ADP Venezuela|ENT .|PUNCT
Its|ADJ consolidated_net_sales|NOUN fell|VERB by|ADP around|ADV 5_per|MONEY cent|NOUN to|ADP Rs|NOUN 3,498.5|CARDINAL crore|NOUN from|ADP Rs_3,695|CARDINAL crore|NOUN of|ADP the|DET period|NOUN in|ADP the_last_year|DATE due|ADP to|ADP lower_North_American_sales|NOUN .|PUNCT
For|ADP the_full_year|DATE FY|PROPN 17|NUM ,|PUNCT consolidated_net_sales|NOUN were|VERB at|ADP Rs_13,866_crore|MONEY ,|PUNCT down|ADV 9_per|MONEY cent|NOUN year|NOUN -|PUNCT on|ADP -|PUNCT year|DATE ,|PUNCT while|ADP the|DET consolidated_net_profit|NOUN stood|VERB at|ADP Rs_1,292_crore|ENT ,|PUNCT down|ADP 39_per|MONEY cent|NOUN over|ADP the_last_year|DATE .|PUNCT
Dr_Reddy’s|ENT has|VERB a|DET vertically_integrated_business_model|NOUN with|ADP three|CARDINAL segments|NOUN —|PUNCT global_generics|NOUN ,|PUNCT pharmaceuticals_services|NOUN and|CCONJ active_ingredients|NOUN ,|PUNCT and|CCONJ proprietary_products|NOUN .|PUNCT
Around_82|CARDINAL per|NOUN cent|NOUN of|ADP its|ADJ revenue|NOUN is|VERB currently|ADV derived|VERB from|ADP global_generics|NOUN .|PUNCT Muted|VERB US_performance|NOUN The|DET revenue|NOUN from|ADP North_America|ENT fell|VERB by|ADP 19_per_cent|PERCENT in|ADP the|DET fourth-quarter|DATE to|ADP Rs_1,535|CARDINAL crore|NOUN as|ADP compared|VERB to|ADP the_same_quarter|DATE in|ADP the_previous_year|DATE ,|PUNCT due|ADP to|ADP pricing_pressure|NOUN and|CCONJ increased|VERB competition|NOUN in|ADP some|DET generics|NOUN such|ADJ as|ADP Valgancyclovir|ENT .|PUNCT
Lack|NOUN of|ADP new_launches|NOUN due|ADJ to|ADP regulatory_clamp-down|NOUN also|ADV impacted|VERB the|DET revenue|NOUN .|PUNCT
The|DET company’s_North_America_business|NOUN has|VERB accounted|VERB for|ADP 43_per|MONEY cent|NOUN of|ADP the|DET overall_revenue|NOUN .|PUNCT
As|ADP on|ADP March_2017|DATE ,|PUNCT cumulatively|ADV ,|PUNCT the|DET company|NOUN has|VERB 101|CARDINAL filings|NOUN pending|VERB (|PUNCT 99|CARDINAL ANDAs|NOUN ,|PUNCT 2|CARDINAL NDAs|NOUN )|PUNCT ,|PUNCT of|ADP which|ADJ 62|CARDINAL are|VERB Para_IV_opportunities|NOUN and|CCONJ 21|CARDINAL FTFs|NOUN .|PUNCT
During|ADP the|DET earning_call|NOUN ,|PUNCT the|DET management|NOUN guided|VERB for|ADP about|ADV 10-plus_launches|NOUN in|ADP FY18|ENT .|PUNCT
Scale|PROPN -|PUNCT up|PART across|ADP Europe|ENT and|CCONJ EM|ENT Gradual|ENT sequential|ADJ improvement|NOUN is|VERB seen|VERB in|ADP the|DET revenue|NOUN from|ADP emerging|VERB markets|NOUN on|ADP account|NOUN of|ADP the|DET appreciation|NOUN in|ADP the|DET Russian_Ruble|PROPN and|CCONJ improving|VERB macros|NOUN across|ADP geographies|NOUN .|PUNCT
The|DET revenue|NOUN from|ADP Russia|ENT for|ADP the_fourth_quarter|DATE grew|VERB by|ADP 26_per|MONEY cent_YoY|NOUN to|ADP Rs_340|CARDINAL crore|NOUN .|PUNCT
Commercialisation|NOUN of|ADP biosimilars|NOUN across|ADP emerging_markets|NOUN has|VERB also|ADV seen|VERB meaningful_traction|NOUN .|PUNCT
The_European_business|ENT reported|VERB strong_growth|NOUN on|ADP a|DET YoY_basis|NOUN on|ADP the|DET back|NOUN of|ADP new_launches|NOUN .|PUNCT
The|DET revenue|NOUN from|ADP India|ENT rose|VERB by|ADP 8_per_cent|PERCENT YoY|NOUN at|ADP Rs_571|CARDINAL crore|NOUN during|ADP the_fourth_quarter|DATE .|PUNCT
This|DET was|VERB impacted|VERB by|ADP demonetisation|NOUN and|CCONJ the|DET effect|NOUN of|ADP price_controls|NOUN .|PUNCT
The_Pharmaceutical_Services|ENT and|CCONJ Active|ADJ Ingredients|NOUN (|PUNCT PSAI|PROPN )|PUNCT business|NOUN ,|PUNCT which|ADJ accounts|VERB for|ADP 15_per|MONEY cent|NOUN of|ADP the|DET company|NOUN ’s_revenue|NOUN ,|PUNCT declined|VERB around|ADP 6_per|MONEY cent_YoY|NOUN during|ADP the_quarter|DATE .|PUNCT
Operating_profit|NOUN was|VERB at|ADP Rs_630|CARDINAL crore|NOUN .|PUNCT
The|DET EBITDA_margin|NOUN for|ADP the_quarter|DATE stood|VERB at|ADP 18_per|MONEY cent|NOUN ,|PUNCT a|DET sequential_decline|NOUN of|ADP 24_per|QUANTITY cent|NOUN from|ADP the_December_quarter|DATE .|PUNCT
(|PUNCT This|DET article|NOUN was|VERB published|VERB on|ADP May_16,_2017|DATE )|PUNCT
